7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
27th March 2017
Morrow Sodali retains Grayling
Global corporate governance consultancy and proxy solicitation firm, Morrow Sodali has appointed Grayling, with a brief to improve the company’s visibility among the capital markets as it seeks to...Read More
3rd March 2017
New Wins for San Francisco
Grayling San Francisco has officially added two new clients to its portfolio of technology clients.Codility streamlines and accelerates tech recruiting. Its assessment platform automates the sourcing,...Read More
2nd March 2017
Grayling taps Suthers for SVP role
Grayling has further strengthened its San Francisco team with the appointment of Elliott Suthers as senior vice president. With more than a decade of communications and policy experience, Suthers...Read More